Evidence map›Paper›PMID 42352983›Full record

ArticleInternational journal of molecular sciences2026

Multifaceted Integrated Analysis of CDK1 and TOP2A Signaling Pathways for Multi-Target Therapeutic Intervention in Epithelial Ovarian Cancer.

Saber Samadiafshar, Mahla Masoudi, Hossein Azizi, Thomas Skutella

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Saber SamadiafsharPediatric Health Research Center, Tabriz University of Medical Sciences, Tabriz 5143377505, Iran.ORCID 0000-0001-9050-009X
Mahla MasoudiDepartment of Stem Cells and Cancer, College of Biotechnology, Amol University of Special Modern Technologies, Amol 4615863111, Iran.
Hossein AziziDepartment of Stem Cells and Cancer, College of Biotechnology, Amol University of Special Modern Technologies, Amol 4615863111, Iran.ORCID 0000-0001-8246-595X
Thomas SkutellaInstitute for Anatomy and Cell Biology, Medical Faculty, University of Heidelberg, Im Neuenheimer Feld 307, 69120 Heidelberg, Germany.ORCID 0000-0003-4813-1213

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) remains one of the most aggressive gynecological malignancies, largely due to late-stage diagnosis, therapeutic resistance, and molecular heterogeneity. This study aimed to identify biologically relevant hub genes and evaluate potential dual-target compounds against

Indexed as

Carcinoma, Ovarian EpithelialCDC2 Protein KinaseDNA Topoisomerases, Type IIOvarian NeoplasmsPoly-ADP-Ribose Binding ProteinsSignal TransductionFemaleGene Expression Regulation, NeoplasticHumansMolecular Docking SimulationMolecular Dynamics SimulationProtein Interaction MapsCDC2 Protein KinaseCDK1 protein, humanDNA Topoisomerases, Type IIPoly-ADP-Ribose Binding ProteinsTOP2A protein, humanCDK1epithelial ovarian cancermolecular dynamics simulationsProtein–Protein Interaction (PPI)TOP2A

Identifiers

PMID42352983
PMCPMC13300235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.